Common Equity: The sum of all common equity items.
BridgeBio Pharma, Inc. (BBIO) had Common Equity of $-2.08B for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$154.18M |
|
$-192.86M |
|
$8.11M |
|
$146.07M |
|
$293.74M |
|
$-139.56M |
|
$-55.19M |
|
$-194.75M |
|
$-194.75M |
|
$-194.63M |
|
$-194.63M |
|
$-194.63M |
|
$-194.63M |
|
$-139.56M |
|
$-132.16M |
|
191.53M |
|
191.53M |
|
$-1.00 |
|
$-1.00 |
|
| Balance Sheet Financials | |
$797.75M |
|
$5.37M |
|
$138.28M |
|
$936.02M |
|
$287.97M |
|
$1.85B |
|
$2.72B |
|
$3.01B |
|
|
Common Equity |
$-2.08B |
$-2.10B |
|
$-2.08B |
|
194.77M |
|
| Cash Flow Statement Financials | |
$-445.91M |
|
$-24.49M |
|
$359.29M |
|
$683.24M |
|
$572.14M |
|
$-111.10M |
|
$133.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.77 |
|
-- |
|
-- |
|
-8.29 |
|
-0.89 |
|
94.74% |
|
-90.52% |
|
-90.52% |
|
-- |
|
-126.32% |
|
-125.09% |
|
$-447.01M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
0.30 |
|
1.11 |
|
81.40 |
|
9.38% |
|
9.25% |
|
-20.79% |
|
87.07% |
|
$-10.66 |
|
$-2.33 |
|
$-2.33 |
|